The values and corporate philosophy that MacroGenics Inc represents are centered around their commitment to discovering and developing innovative biopharmaceutical products. The company strives to deliver impactful medicines to improve the lives of patients. MacroGenics Inc focuses on excellence, integrity, and collaboration in their research and development efforts. They aim to be a trusted partner and create value for their stakeholders through their cutting-edge science and dedication to advancing healthcare. With a focus on science-driven discovery and a patient-centric approach, MacroGenics Inc aims to bring transformative therapies to market.

MacroGenics Inc is primarily present in the United States.

MacroGenics Inc, a renowned biopharmaceutical company, has achieved several significant milestones in its impressive journey. Notably, the company successfully developed and received regulatory approvals for multiple clinical-stage product candidates, showcasing its commitment to advancing innovative therapies. MacroGenics Inc's most notable achievement includes the FDA approval of margetuximab, a treatment for patients with HER2-positive metastatic breast cancer. Moreover, the company has established strategic collaborations with leading pharmaceutical companies, further validating its research and development capabilities. With its strong focus on precision medicine and novel antibody-based therapeutics, MacroGenics Inc continues to drive breakthrough advancements in the field of biotechnology.

MacroGenics Inc is a biopharmaceutical company based in Rockville, Maryland. Established in 2000, MacroGenics has been dedicated to developing innovative antibody-based therapies for patients with cancer and autoimmune disorders. With a strong focus on research and development, the company has built a robust pipeline of product candidates targeting different diseases. MacroGenics has achieved several milestones, including FDA approvals and collaborations with notable pharmaceutical companies. With its experienced team and cutting-edge technology, MacroGenics continues to strive towards improving patients' lives through the development of novel therapies.

The main competitors of MacroGenics Inc in the market include larger pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, and Novartis. These companies also operate in the biopharmaceutical industry and have a similar focus on developing innovative therapies and treatments. MacroGenics Inc faces competition from these established players in terms of product development, market share, and financial performance. However, MacroGenics Inc has its own unique portfolio of proprietary drug candidates and strategic collaborations which help it remain competitive in the market.

MacroGenics Inc is primarily active in the biotechnology industry.

The business model of MacroGenics Inc is focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary technology platforms to discover, design, and optimize monoclonal and multi-specific antibodies. By leveraging its expertise in antibody engineering and targeting mechanisms, MacroGenics aims to create novel therapies that have the potential to improve patient outcomes. With a strong pipeline of product candidates targeting various cancer indications, MacroGenics Inc strives to advance medical innovation and bring transformative treatments to patients in need.

De MacroGenics K/W is -1,44.

De MacroGenics KUV is 3,86.

De AlleAktien Kwaliteitsscore voor MacroGenics is 3/10.

De verwachte MacroGenics omzet is 67,40 mln. USD.

De verwachte MacroGenics winst is -180,90 mln. USD.

MacroGenics Inc is a biopharmaceutical company that focuses on developing immunotherapy products for cancer and autoimmune diseases. The company aims to develop innovative therapies that can improve the lives of patients. The business model of MacroGenics comprises three main divisions: research, development, and commercialization. The company investigates the mechanisms behind the immune system to develop targeted products that can enhance immune control in diseases. To do this, the company utilizes its proprietary technology platform, the Dual-Affinity Re-Targeting (DART) technology. MacroGenics' research division focuses on the development of novel immunotherapies. An important focus is on the development of bispecific antibodies (BiTEs), which can specifically recognize and target two different antigens on tumor cells. The company already has several such products in the development phase, including MGD015, MGD017, and MGD019. MacroGenics' development division is involved in the manufacturing and testing of therapeutics and drugs that have emerged from the research division. The company has several products on the market, including the cancer immunotherapy Margetuximab (Margenza®) and Aes-103, a nasal spray for pain in cancer patients. The commercialization division of MacroGenics is responsible for the global marketing of the company's products. It also works closely with licensees and partners. One important partner of MacroGenics is Incyte Corporation, with whom the company collaborates on the development of cancer immunotherapies. MacroGenics also pursues a diversification strategy and expands into new therapy areas. The company recently entered into a partnership with Zai Lab Ltd. to jointly develop a novel antibody-drug conjugate (ADC) against HER2-positive cancer. The company has also initiated a program for the development of drugs for autoimmune diseases, including therapeutic antibodies. In addition to its commercial products, MacroGenics is also a leading provider of research services in the field of antibody and protein engineering and manufacturing. The company offers customized solutions for customers in the academic, pharmaceutical, and biotechnology sectors. Overall, MacroGenics' business model is aimed at advancing the development of innovative immunotherapy products and marketing them worldwide. With a broad product portfolio and an extensive research and development pipeline, the company is in a strong position to ensure the growth and success of the company in the future.

MacroGenics keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor MacroGenics of het bedrijf keert geen dividend uit.

De ISIN van MacroGenics is US5560991094.

Het WKN van MacroGenics is A1W6ND.

De ticker van MacroGenics is MGNX.

Binnen de laatste 12 maanden betaalde MacroGenics een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal MacroGenics naar verwachting een dividend van 0 USD betalen.

De dividendrendement van MacroGenics is momenteel .

MacroGenics betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

MacroGenics betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

MacroGenics wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van MacroGenics van 8-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 8-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 8-7-2024.

In het jaar 2023 heeft MacroGenics 0 USD aan dividenden uitgekeerd.

De dividenden van MacroGenics worden in USD uitgekeerd.